ANNUAL REPORT 2012 - TiGenix

Cx911 (regulatory T-cell platform) :
- “Cell populations having immunoregulatory
activity, methods for the preparation and
uses thereof.” (PCT Publication Number
WO/2011/048222) : a family of pending EP;
US & JP patent applications protecting a
method for the preparation of regulatory
T-cells using ASC, the use thereof in the
therapy of diseases and kits comprising
said cells.
- “Cell populations having immunoregulatory
activity, methods for the preparation and
uses thereof.” (PCT Publication Number
WO/2012/156522) : a PCT patent application
protecting a method for the preparation
of regulatory T-cells using ASC, the use
thereof in the therapy of diseases and kits
comprising said cells.
An overview of TiGenix’s patent portfolio
is included in Section A of “Appendix 1 :
Overview of Patents and Trademarks”.
Trademark Portfolio
The TiGenix brand is protected by trademarks
applications or registered “TiGenix”
trademark in 13 European jurisdictions,
Canada and the US. Additional protection
is provided by the “Living Medicines” brand
registered as a community trademark. The
ChondroCelect brand name is protected by
applications or registered trademarks in 12
European jurisdictions, Canada and the US.
Prospective product names have been
registered primarily as CTM word trademarks
to protect the brands MeniscoCelect,
CCH, Idryon, Ontaril, Miredal, Alocellix,
Adicell-X and Alofisel. Benelux trademarks
are also registered for the brands CCI and
Chondroboost. US trademarks are also
registered or are pending registration for
the brands CCI, CCH and MeniscoCelect. A
Canadian trademark application is pending
registration for CCH.
Trademarks have also been previously
registered or are applied for to protect the
Cellerix brand, and include registered CTM
trademarks Cellerix (graphic), Cellerix (word),
Cellerix living medicines and US trademark
applications for Cellerix (graphic) and
Cellerix Living Medicines (word).
An overview of TiGenix’s trademark portfolio
is included in Section B of “Appendix 1 :
Overview of Patents and Trademarks”.
Other Proprietary Rights
TiGenix believes that part of its intangible
assets is represented by several elements of
its cell therapy program involving unpatented
proprietary technology, processes, knowhow,
or data, including cell isolation,
production and release processes. With
respect to proprietary technology, knowhow
and data which are not patentable or
potentially patentable, or processes other
than production processes for which patents
are difficult to enforce, TiGenix has chosen to
protect its interests by relying on trade secret
protection and confidentiality agreements
with its employees, consultants and certain
contractors and collaborators. All employees
at TiGenix are parties to employment
agreements that include confidentiality
agreements.
Freedom to Operate
In regard to the Cx601 and Cx611 products,
freedom to operate analyses have been
carried out by independent legal counsel in
the US and Europe of the cell therapy product,
76 TiGenix I annual report 2012